Abstract: The present disclosure relates to the technical field of chemical engineering, and specifically discloses a method for removing oxygenated compounds from a Fischer-Tropsch oil having a high carbon number. A reaction-extraction combined process is used in this method for removing oxygenated compounds from a Fischer-Tropsch oil having a high carbon number, wherein the Fischer-Tropsch oil (C5-C20) is firstly subjected to alkaline washing with an alkaline aqueous solution to convert acidic substances into water-soluble salts. The Fischer-Tropsch oil is subjected to a primary extraction with a carbonate-based extractant to remove alcohols and esters therein, and subsequently subjected to a secondary extraction with propylene carbonate to remove ketones and aldehydes impurities therein, thereby removing oxygenated compounds in the Fischer-Tropsch oil. After extraction, the content of the oxygenated compounds in the Fischer-Tropsch oil may be down to 1-60 ppm, and the yield of oil product may be kept 90% or more.

Abstract: Disclosed are a checking apparatus, a backend apparatus, a checking management system, and a checking method. The checking apparatus comprises: a navigation trolley and a liftable checking module, wherein the liftable checking module is arranged on the navigation trolley, the liftable checking module moves under control of the navigation trolley so as to obtain, through the movement, depth information of an article pile to be checked, and the navigation trolley is used for determining side length information of the article pile based on the depth information, determining a checking result for the article pile based on the side length information, and sending the checking result to the backend apparatus.

Abstract: This application provides a carrying device, a transport robot, an inventory method, and an inventory system. The transport robot includes a carrying device. The carrying device includes: a bracket; a tray, mounted to the bracket and configured to place goods; a weight detection device, configured to detect a weight of the goods placed on the tray; and a retractable arm assembly, configured to push the goods placed on the tray out of the tray or pull the goods to the tray. Compared with the prior art, the weight detection device is arranged on the tray of the carrying device to detect the weight of the goods placed on the tray. The quantity of the goods may be determined according to the weight of the goods. Therefore, the low goods carrying efficiency due to manual goods inventory is avoided.

Abstract: The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.

Abstract: The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.

Abstract: The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.

Abstract: The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.